Physician profile
Robert Walters
NPI 1548482482
$4,620.64
in general payments reported to CMS, 2019-2025
23 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $24.14 · 2021: $69.67 · 2022: $45.56 · 2023: $407 · 2024: $1,647 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,765 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,765.45 |
| Education | $169.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,184.48 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $702.61 | 2019-2025 | |
| Amgen INC. | $396.49 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $369.25 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $269.61 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Leo Pharma INC. | $248.14 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $239.31 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $238.64 | 2023-2025 | |
| Galderma Laboratories, L.P. | $228.77 | 2019-2025 | Nemluvio |
| Pfizer INC. | $213.61 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $91.94 | 2023-2025 | Dupixent |
| Dermavant Sciences, INC. | $66.22 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $54.82 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $48.58 | 2024 | Sotyktu |
| Genentech USA, INC. | $48.39 | 2019-2024 | Xolair |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $47.70 | 2025 | Apligraf, Cygnus Dual |
| Sun Pharmaceutical Industries INC. | $43.58 | 2023-2025 | Blu-U |
| Hill Dermaceuticals, INC. | $26.05 | 2024 | Tolak |
| Celgene Corporation | $24.12 | 2019 | |
| Sandoz INC. | $23.31 | 2024 | Hyrimoz |
| Mayne Pharma Commercial LLC | $22.70 | 2025 | |
| Incyte Corporation | $17.25 | 2024 | Opzelura |
| Botanix Sb INC | $15.07 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Walters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.